Quoin Pharmaceuticals Ltd (QNRX): Price-to-Projected Revenue Ratio

Public company logo of Quoin Pharmaceuticals Ltd. (QNRX)

Quoin Pharmaceuticals (QNRX) is focusing its development on clinical trials for treatments targeting rare genetic skin pathologies. The forward price-to-sales valuation illustrates this trend, with the latest reading at . The foundation for growth is exceptional pricing power derived from the patent for the drug QRX-003. Meanwhile, risk is posed by biotech behemoths seeking to acquire promising orphan drug developments to dominate the dermatology sector.

Quoin Pharmaceuticals Ltd - QNRX Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/17/2026)

Comprehensive metric breakdowns and analytics for Quoin Pharmaceuticals Ltd (QNRX)

Fundamental valuation:Quoin Pharmaceuticals Ltd. QNRX
Manufactured products of Quoin Pharmaceuticals Ltd.

Forward P/S relates current market capitalization to expected revenue, reflecting the valuation's sensitivity to future cash flow forecasts. For Quoin Pharmaceuticals (QNRX), which is developing a pipeline of drugs for rare dermatoses, this indicator assesses the commercialization potential of QRX-003, allowing the company's forward P/S chart to determine whether the market price is fair relative to sales prospects.